Throughout the world, public policies are evolving with regard to biosimilar (large molecule) pharmaceutical products. The associated issues involve scientific, political, legal, and economic questions. This paper examines the state of the economic debate in the US as the US Food and Drug Administration formulates its process for approving biosimilar products. Due to differences in biosimilar and small molecule products, regulatory experience gained from the success of generic small molecule products in the US and elsewhere is not necessarily a useful guide.
You are not authenticated to view the full text of this chapter or article.
Get access to the full article by using one of the access options below.
Pay to Access Content (PDF download and unlimited online access)